GlaxoSmithKline (GSK) has agreed to acquire Nuvalent, a biotech focused on targeted therapies for solid tumors, in a deal valued at roughly $10.6 billion. The acquisition centers on Nuvalent's pipeline of next-generation kinase inhibitors, specifically for patients with certain genetic subtypes of non-small cell lung cancer (NSCLC).
At the heart of the deal are two investigational drugs: zidesamtinib (NVL-520), a ROS1 inhibitor, and eladalkib (NVL-655), an ALK inhibitor. Both are designed to be brain-penetrant and are being positioned by the company as potential best-in-class therapies. Nuvalent has described them as highly selective, next-generation treatments aimed at overcoming resistance to existing targeted agents.
The U.S. Food and Drug Administration has set target action dates for the regulatory reviews of both drugs. Zidesamtinib's PDUFA date is September 18, while eladalkib's deadline falls on November 27. These dates mark the decision points for potential U.S. approvals, which would be the first for either drug.
For GSK, the acquisition bolsters its oncology portfolio with two late-stage assets in a high-value lung cancer market. The deal underscores the firm's bet on precision medicine, where drugs are matched to specific tumor mutations. It also positions GSK to compete directly with existing ROS1 and ALK inhibitors from companies like Pfizer and Roche.
Investors will watch for regulatory outcomes and whether clinical data ultimately support the best-in-class claims. The deal also carries execution risk: integrating a pipeline of unapproved drugs, and the possibility that competitors could launch similarly effective agents before or after the FDA decisions.